David Scott Jones
Net Worth

Last updated:

What is David Scott Jones net worth?

The estimated net worth of Mr. David Scott Jones is at least $5,198,443 as of 9 Feb 2024. He owns shares worth $419,100 as insider, has earned $1,759,143 from insider trading and has received compensation worth at least $3,020,200 in EyePoint Pharmaceuticals, Inc..

What is the salary of David Scott Jones?

Mr. David Scott Jones salary is $604,040 per year as Senior Vice President & Chief Commercial Officer in EyePoint Pharmaceuticals, Inc..

How old is David Scott Jones?

Mr. David Scott Jones is 58 years old, born in 1967.

What stocks does David Scott Jones currently own?

As insider, Mr. David Scott Jones owns shares in one company:

Company Title Shares Price per share Total value
EyePoint Pharmaceuticals, Inc. (EYPT) Senior Vice President & Chief Commercial Officer 37,962 $11.04 $419,100

What does EyePoint Pharmaceuticals, Inc. do?

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT logo
EYPT
EyePoint Pharmaceuticals, Inc.
$11.04

David Scott Jones insider trading

EyePoint Pharmaceuticals, Inc.

Mr. David Scott Jones has made 11 insider trades between 2020-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 41,050 units of EYPT stock on 30 Jun 2020. As of 9 Feb 2024 he still owns at least 37,962 units of EYPT stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 4,967 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Restricted Stock Units 4,967 N/A N/A
Option
Restricted Stock Units 5,000 N/A N/A
Option
Stock Option (Right to Buy) 209 $11.47 $2,397
Sale
Common Stock 209 $28.49 $5,954
Option
Common Stock 209 $11.47 $2,397
Option
Stock Option (Right to Buy) 16,413 $3.26 $53,506
Option
Common Stock 16,413 $3.26 $53,506
Option
Stock Option (Right to Buy) 9,604 $12.9 $123,892
Sale
Common Stock 9,604 $25.27 $242,722
Sale
Common Stock 16,413 $25.45 $417,662
Option
Common Stock 9,604 $12.9 $123,892
Option
Stock Option (Right to Buy) 300 $12.9 $3,870
Option
Stock Option (Right to Buy) 300 $3.26 $978
Option
Common Stock 300 $3.26 $978
Sale
Common Stock 300 $25 $7,500
Option
Common Stock 300 $12.9 $3,870
Sale
Common Stock 300 $25 $7,500
Sale
Common Stock 5,600 $25.01 $140,067
Sale
Common Stock 5,700 $25.01 $142,551
Option
Stock Option (Right to Buy) 5,600 $12.9 $72,240
Option
Common Stock 5,700 $3.26 $18,582
Option
Stock Option (Right to Buy) 5,700 $3.26 $18,582
Option
Common Stock 5,600 $12.9 $72,240
Option
Common Stock 400 $12.9 $5,160
Option
Stock Option (Right to Buy) 500 $3.26 $1,630
Sale
Common Stock 400 $25 $10,000
Sale
Common Stock 500 $25 $12,500
Option
Stock Option (Right to Buy) 400 $12.9 $5,160
Option
Common Stock 500 $3.26 $1,630
Option
Stock Option (Right to Buy) 28,750 $10.13 $291,238
Option
Stock Option (Right to Buy) 5,416 $11.47 $62,122
Option
Common Stock 28,750 $10.13 $291,238
Option
Common Stock 5,416 $11.47 $62,122
Sale
Common Stock 28,750 $22.69 $652,251
Sale
Common Stock 5,416 $22.24 $120,436
Option
Restricted Stock Units 15,285 N/A N/A
Option
Common Stock 15,285 N/A N/A
Option
Restricted Stock Units 4,967 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Common Stock 4,967 N/A N/A
Option
Restricted Stock Units 5,000 N/A N/A
Option
Common Stock 4,105 N/A N/A
Option
Restricted Stock Units 4,105 N/A N/A
Option
Common Stock 4,966 N/A N/A
Option
Restricted Stock Units 4,966 N/A N/A
Option
Restricted Stock Units 4,105 N/A N/A
Option
Common Stock 4,105 N/A N/A
Option
Restricted Stock Units 41,050 N/A N/A
Option
Common Stock 41,050 N/A N/A

EyePoint Pharmaceuticals key executives

EyePoint Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: